Women's health, breast health a review of the gynecologic effects of breast cancer

Obstetrical and Gynecological Survey

Volumn 64, Issue 7, 2009, Pages 469-480

  Goldman, Mindy ^a,b   O'Hair, Kim ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Women's Health   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CLOMIFENE CITRATE; CLONIDINE; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN; EXEMESTANE; FOLLITROPIN; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LETROZOLE; NORETHISTERONE; PAROXETINE; POLYCARBOPHIL; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TIBOLONE; VENLAFAXINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADENOCARCINOMA; AMENORRHEA; ARTHRALGIA; BONE PAIN; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CRYOPRESERVATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG WITHDRAWAL; ENDOMETRIOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; FAMILY HISTORY; FEMALE FERTILITY; FEMALE INFERTILITY; FEMALE SEXUAL DYSFUNCTION; FERTILIZATION IN VITRO; GENE MUTATION; GENETIC COUNSELING; GYNECOLOGY; HETEROZYGOTE; HOT FLUSH; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LEIOMYOSARCOMA; LIBIDO; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; OLIGOMENORRHEA; ONCOGENE; OSTEOPOROSIS; OVARY FUNCTION; PATIENT COMPLIANCE; PERITONEUM CANCER; POLYP; PREGNANCY; PREMENOPAUSE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; SLEEP DISORDER; SPERM DONOR; TERATOGENICITY; TRANSVAGINAL ECHOGRAPHY; UTERUS DISEASE; UTERUS MYOMA; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINAL PRURITUS; VASOMOTOR DISORDER; WOMEN'S HEALTH; BREAST TUMOR; FEMALE; GYNECOLOGIC DISEASE; PREGNANCY COMPLICATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 70349561223     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181a713f1     Document Type: Review

References (125)

1. American Cancer Society statistics. Available at: www. cancer.org.
2. Hayat M, Howlader N, Reichman M, et al. Cancer statistics, trends and multiple primary cancer analysis from the Surveillance, Epidemiology and End Results (SEER) program. Oncologist 2007; 12:20-37. (Pubitemid 46143500)
3. Partridge AH, Gelber S, Peppercorn J, et al. Web-Based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22:4174-4183. (Pubitemid 41185188)
4. Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 2004; 15:1065-1071. (Pubitemid 39089783)
5. Davis AL, Klitus M, Mintzer DM. Chemotherapy-induced amenorrheafrom adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer 2005; 6:421-424. (Pubitemid 43078897)
6. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344:1997-2008. (Pubitemid 32568155)
7. Lower EE, Blau R, Gazder P, et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Women's Health Gend Based Med 1999; 8:949-954. (Pubitemid 29501939)
8. Partridge AH, Gelber S, Gelber R, et al. Delayed premature menopause following chemotherapy for early stage breast cancer: long term results from IBSCG Trial V. Proc Am Soc Clin Oncol 2005; 16s:50s.
9. Porcu E, Fabbri R, Damiano G, et al. Oocyte cryopreservation in oncological patients. Eur J Obstet Gynecol Reprod Biol 2004; 113:S14-S16.
10. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353:318-321. (Pubitemid 41058339)
11. Salhab M, Al Sarakbi W, Mokbel K. In vitro fertilization and breast cancer risk: a review. Int J Fértil Womens Med 2005; 50:259-266.
12. Williamson JG, Ellis JD. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw 1973; 80:844-847.
13. Mitwally MFM, Casper RF. Aromatase inhibition reduces gonadotrophs dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003; 18: 1588-1597.
14. Azim AA, Costantini-Ferrando M, Oktay K, et al. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008; 26:2630-2635.
15. Ataya K, Rao LV, Lawrence E, et al. Luteinizing hormonereleasing hormone agonist inhibits cyclophosphamideinduced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52:365-372.
16. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620-1626. (Pubitemid 26318897)
17. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryos, oocytes, or ovaries. Oncologist 2007; 12:1044-1054. (Pubitemid 350007016)
18. Goodwin PJ, Oktay KH, Lobo RA. Options for preservation of fertility in women. N Engl J Med 2005; 353:1418-1420.
19. Berry D, Theriault R, Holmes F, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855-861. (Pubitemid 29109315)
20. Ishida T, Yokoe T, Kasumi F, et al. Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res 1992; 83:1143-1149. (Pubitemid 23009034)
21. Kothari AS, Fentiman IS. Breast cancer in young women [review]. Int J Clin Pract 2002; 56:184-187. (Pubitemid 34477200)
22. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107:1219-1226. (Pubitemid 44452769)
23. Ring A, Smith IE, Ellis PA. Breast cancer in pregnancy. Ann Oncol 2005; 16:1855-1860.
24. Sharp C, Shrimpton JC, Bury RF. Diagnostic Medical Exposures: Advice on Exposure to Ionizing Radiation During Pregnancy. London, UK: National Radiological Protection Board, 1998.
25. Mueller BA, Simon MS, Deapen D, et al. Childbearing and survival after breast carcinoma in young women. Cancer 2003; 98:1131-1140. (Pubitemid 37099897)
26. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451-1467.
27. Thürlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG) 1-98 Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [Erratum in: N Engl J Med 2006; 354: 2200]. N Engl J Med 2005; 353:2747-2757.
28. Howell A, Cuzick J, Baum M, et al; ATAC Trialists' Group. (Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
29. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J Natl Cancer Inst 2005; 97:1262-1271. (Pubitemid 41535367)
30. Coombes RC, Kilburn LS, Snowdon CF, et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007; 17:559-570.
31. Jakesz R, Jonat W, Gnant M, et al; ABCSG; the GABG. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
32. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23:5138-5147. (Pubitemid 46224022)
33. Cohen I, Figer A, Tepper R, et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 1999; 72:202-207. (Pubitemid 29093776)
34. Mourits MJ, de Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97:855-866. (Pubitemid 32406196)
35. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer. A review. J Clin Oncol 1991; 9:1283-1297.
36. Mourits MJ, de Vries EG, Willemse PH, et al. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer 1999; 79:1761-1764. (Pubitemid 29132301)
37. Chalas E, Constantino D, Wickerham N. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005; 192:1230-1237.
38. Iguchi T, Hirokawa M, Takasugi M. Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology 1986; 42:1-11. (Pubitemid 17172661)
39. Diwan BA, Anderson LM, Ward JM. Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen. Carcinogenesis 1997; 18:2009-2014.
40. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast 2004; 13:446-451.
41. Mortimer JE, Boucher L, Baty J, et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999; 17:1488-1492. (Pubitemid 29220856)
42. Ganz PA, Coscarelli A, Fred C, et al. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 1996; 38:183-199. (Pubitemid 26102146)
43. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994; 343: 1318-1321.
44. Cohen I, Rosen DJD, Altaras MM, et al. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formation and fibroid overgrowth. Br J Cancer 1994; 63:620-621. (Pubitemid 24076494)
45. Ugwumadu AHN, Harding K. Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the antioestrogen tamoxifen. Eur J Obstet Gynecol 1994; 54:153-156. (Pubitemid 24170237)
46. Ford MR, Turner MJ, Wood C, et al. Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol 1988; 158:1119.
47. Cohen I, Beyth Y, Tepper R, et al. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol 1995; 58:86-91.
48. Cheng WF, Lin HH, Torng PL, et al. Comparison of endometrial changes among symptomatic tamoxifen treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997; 66:233-237. (Pubitemid 27335409)
49. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361:296-300. (Pubitemid 36126189)
50. Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356:881-887.
51. Dallenbach-Hellweg G, Schmidt D, Hellberg P, et al. The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet 2000; 263:170-177. (Pubitemid 30251425)
52. Treilleux T, Mignotte H, Clement-Chassagne C, et al. Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature. Eur J Surg Oncol 1999; 25:477-482. (Pubitemid 29462336)
53. Saadat M, Truong PT, Kader HA, et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer 2007; 110:31-37. (Pubitemid 46986415)
54. Ferguson SE, Soslow RA, Amsterdam A, et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006; 101:322-326.
55. Gerber B, Krause A, Müller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18:3464-3470. (Pubitemid 30783324)
56. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006; 99: 215-220.
57. Jakesz R, Jonat W, Gnant M, et al; ABCSG, the GABG. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
58. Duffy S, Jackson TL, Lansdown M, et al. The ATAC ('Arimidex,' Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006; 21:545-553. (Pubitemid 43159936)
59. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092. (Pubitemid 38298988)
60. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802. (Pubitemid 37362955)
61. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802-1810.
62. Reich O, Regauer S. Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 2007; 19:347-352. (Pubitemid 46883524)
63. Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994; 78:736-743.
64. Ailawadi RK, Jobanputra S, Kataria M. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004; 81:290-296. (Pubitemid 38223905)
65. Shozu M, Murakami K, Inoue M, et al. Aromatase and Leomyoma of the Uterus Semin Reprod Med 2004; 22:51-609.
66. Land SR, Wickerham DL, Constantino JP, et al. Patientreported symptoms and quality of life during treatment with tamoxifen or raloxifen for breast cancer prevention. The NSABP study of tamoxifen and raloxifen (STAR) P-2 Trial. Obstet Gynecol Surv 2006; 61:651-653.
67. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009; 9:51-60.
68. Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006; 9:49-58. (Pubitemid 43155683)
69. Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000; 92: 1054-1064. (Pubitemid 30618024)
70. Nachtigall LE, Nachtigall MJ. Menopausal changes, quality of life, and hormonetherapy. Clin Obstet Gynecol 2004; 47: 485-488.
71. Holmberg L, Anderson H. HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomized camparison: trial stopped. Lancet 2004; 363:453-455. (Pubitemid 38210063)
72. Bordeleau L, Pritchard K, Goodwin P, et al. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. 2007; 29:230-241.
73. Low Dog T. Menopause: a review of botanical dietary supplements. Am J Med 2005; 118:985.
74. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. Pharmacol Res 2008; 58:8-14.
75. Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105:161-166. (Pubitemid 40189927)
76. Stearns V. Clinical update: new treatments for hot flushes. Lancet 2007; 369:2062-2064. (Pubitemid 46935929)
77. Speroff L, Gass M, Constantine G, et al. Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111:77-87.
78. Loibl S, Schwedler K, von Minckwitz G, et al. Venlafaxine is superior to Clonidine as treatment of hot flashes in breast cancer patients-a double-blind, randomized study. Ann Oncol 2007; 18:689-693. (Pubitemid 46523272)
79. Loprinzi L, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77: 1159-1163. (Pubitemid 35266363)
80. Guttuso T Jr, Kurlan R, McDermott MP, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101:337-345. (Pubitemid 36170136)
81. Pandya KJ, Morrow GR, Roscoe JA. Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet 2005; 366:818-824.
82. Brown JN, Wright BR. Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy 2009; 29:74-81.
83. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, doubleblind, placebo-controlled trial. BJOG 2005; 112:228-233. (Pubitemid 40188253)
84. Modelska K, Cummings S. Tibolone for postmenopausal women: systematicreview of randomized trials. J Clin Endocrinol Metab 2002; 87:16-23. (Pubitemid 34084663)
85. Pastore LM, Carter RA, Hulka BS, et al. Self-reported urogential symptoms in postmenopausal women: women's health initiative. Maturitas 2004; 49:292-303. (Pubitemid 39505183)
86. Bachman GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004; 11:120-130. (Pubitemid 40362209)
87. Bygdeman M, Swahn ML. Replens versus dienostrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996; 23:259-263. (Pubitemid 26000605)
88. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997; 15:969-973. (Pubitemid 27106279)
89. Gabrielsson J, Wallenbeck I, Larsson G, et al. New kinetic data on estradiol in light of the vaginal ring concept. Maturitas 1995; 22(suppl):35-39. (Pubitemid 26021028)
90. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997; 71:73-80. (Pubitemid 27045856)
91. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6:45-52.
92. Hickey M, Saunders C, Partridge A, et al. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008; 19:1669-1680.
93. Landgren MB, Coelingh Bennink HJT, Engelen S. Doseresponse analysis of effects of tibolone on climacteric symptoms. Br J Obstet Gynaecol 2002; 109:1109-1114. (Pubitemid 35287079)
94. Rioux JE, Devlin C, Gelfand MM. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7: 156-161.
95. Kendall A, Dowsett M, Folkerd E, et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17:584-587.
96. Hammar M, Christau S, Nathoorst-Böös J, et al. A doubleblind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105:904-911. (Pubitemid 28423508)
97. Morris EP, Wilson POG, Robinson J, et al. Long-term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999; 106:954-959. (Pubitemid 29415627)
98. Swanson SG, Drosman S, Helmond FA, et al. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006; 13:917-925. (Pubitemid 44760384)
99. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-caner patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. The Lancet Oncology 2009, 10:135-146
100. Berger AM, Kuhn BR, Farr LA, et al. Behavorial therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology 2008 (in press).
101. Lee K, Cho M, Miaskowski C, et al. Impaired sleep and rhythms in persons with cancer. Sleep Med Rev 2004;8:199-212. (Pubitemid 38715678)
102. Knobf MT, Musanti R, Dorward J. Exercise and quality of life outcomes in patients with cancer. Seminin Oncol Nurs 2007; 23:285-296.
103. Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002; 77(suppl 4):S42-S48.
104. Greendale GA, Petersen L, Zibecchi L, et al. Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 2001; 8:111-119. (Pubitemid 32199676)
105. Rowland JH, Desmond KA, Meyerowitz BE, et al. Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors [Erratum in: J Natl Cancer Inst 2001;93:68]. J Natl Cancer Ins 2000; 92:1422-1429.
106. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001; 4:28-41. (Pubitemid 32448485)
107. Segraves RT, Clayton A, Croft H, et al. Buproprion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004; 3:339-342. (Pubitemid 38658043)
108. Kingsberg SA, Simon JA, Goldstein I. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2008; 5(suppl 4):182-193; quiz 193.
109. Krychman ML, Stelling CJ, Carter J, et al. A case series of androgen use in breast cancer survivors with sexual dysfunction. J Sex Med 2007; 4:1769-1774. (Pubitemid 47616872)
110. Mirza FS, Prestwood KM. Bone health and aging: implications for menopause. Endocrinol Metab Clin N Am 2004; 33: 741-759. (Pubitemid 39388983)
111. Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: results from the Women's Health initiative Observational Study. Arch Intern Med 2005; 165: 552-558. (Pubitemid 40344388)
112. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clinical Oncol 2001; 19:3306-3311. (Pubitemid 32642182)
113. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clini Oncol 2000; 18: 1570-1593. (Pubitemid 30205404)
114. Briot K, Tremollieres F, Thomas T, et al. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007; 74:24-31.
115. Hirbe A, Morgan EA, Uluckan O, et al. Skeletal complications of breast cancer therapies. Clin Cancer Res 2006; 12(suppl 20):6309s-6314s.
116. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Seminin Oncol 2003; 30:763-775. (Pubitemid 38010130)
117. Shapiro CL, Phillips G, Poznak CH, et al. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2005; 90:41-46. (Pubitemid 40487000)
118. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42:1044-1051.
119. Easton DF. Familial risks of breast cancer. Breast Cancer Res 2002; 4:179-181.
120. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408. (Pubitemid 27208598)
121. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62:676-689. (Pubitemid 28164626)
122. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 15:1317-1325. (Pubitemid 39223222)
123. Rebbeck TR, Friebel T, Lyncg HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055-1062. (Pubitemid 41095038)
124. Rebbeck TR, Levin AM, Eisen A. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91:1475-1479. (Pubitemid 29424552)
125. Eisen A, Lubinski J, Klijn J. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23:7491-7496. (Pubitemid 46291812)